Pharming Group Nv Stock Short Ratio
| PHAR Stock | USD 7.65 0.12 1.59% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Stock. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group stock.
Pharming |
Pharming Group NV Company Short Ratio Analysis
Pharming Group's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Pharming Group Short Ratio | 1.32 X |
Most of Pharming Group's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Pharming Group NV has a Short Ratio of 1.32 times. This is 66.15% lower than that of the Biotechnology sector and 82.19% lower than that of the Health Care industry. The short ratio for all United States stocks is 67.0% higher than that of the company.
Pharming Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.Pharming Group is currently under evaluation in short ratio category among its peers.
Pharming Fundamentals
| Return On Equity | -0.0818 | ||||
| Return On Asset | -0.0138 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 463.77 M | ||||
| Shares Outstanding | 67.84 M | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 9.62 K | ||||
| Price To Earning | 41.53 X | ||||
| Price To Book | 2.26 X | ||||
| Price To Sales | 1.79 X | ||||
| Revenue | 245.32 M | ||||
| Gross Profit | 188.06 M | ||||
| EBITDA | 9.88 M | ||||
| Net Income | (9.55 M) | ||||
| Cash And Equivalents | 189.96 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 171.54 M | ||||
| Debt To Equity | 0.75 % | ||||
| Current Ratio | 5.22 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (17.3 M) | ||||
| Short Ratio | 1.32 X | ||||
| Earnings Per Share | (0.27) X | ||||
| Target Price | 33.5 | ||||
| Number Of Employees | 382 | ||||
| Beta | 0.81 | ||||
| Market Capitalization | 510.8 M | ||||
| Total Asset | 462.85 M | ||||
| Retained Earnings | (265.26 M) | ||||
| Working Capital | 238.37 M | ||||
| Net Asset | 462.85 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.